From ABCD to E for endothelin in resistant hypertension
- PMID: 36603580
- DOI: 10.1016/j.cell.2022.12.014
From ABCD to E for endothelin in resistant hypertension
Abstract
The potent vasoconstrictor peptide endothelin-1 has long been recognized as a physiological regulator of vascular tone. However, pharmacological blockade of the endothelin-1 pathway has few proven indications thus far. A recent clinical trial for resistant hypertension published in The Lancet may yet herald a new era for endothelin receptor antagonists into the clinical mainstream.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.P.D. is a co-investigator for the Medical Research Council Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) Trial.
Comment on
-
Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.Lancet. 2022 Dec 3;400(10367):1927-1937. doi: 10.1016/S0140-6736(22)02034-7. Epub 2022 Nov 7. Lancet. 2022. PMID: 36356632 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
